ReviewWorld journal of surgical oncology2025
Primary small cell neuroendocrine carcinoma of the urinary tract: a case report and literature review.
Review in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Primary small-cell neuroendocrine carcinoma of the bladder: a very rare histological subtype.Oxford medical case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundSmall cell neuroendocrine carcinoma of the urinary tract (SCC-UT) is an extremely rare genitourinary tumor, which is highly aggressive, prone to local or distant metastasis and has a very poor prognosis. CASE PRESENTATION: This article reports a case of primary small cell neuroendocrine carcinoma of the ureter combined with invasive uroepithelial carcinoma. The patient underwent robot-assisted laparoscopic radical left nephrectomy, full-length ureteral resection, sleeve cystectomy, and pelvic lymph node dissection after exclusion of contraindications to surgery (preoperative assessment confirmed the absence of cardiopulmonary or coagulation abnormalities) and underwent 6 cycles of post operative etoposide/cisplatin adjuvant chemotherapy.
conclusionsThis case underscores the potential efficacy of multimodal therapy, combining robot-assisted surgical resection with adjuvant etoposide/cisplatin chemotherapy, in the management of primary small cell neuroendocrine carcinoma. The patient was detected no local or distant metastases, at 9 months postoperatively. However, the follow-up period of only 9 months is relatively short, which limits the long-term assessment of recurrence or survival. These findings provide a reference for clinical decision-making and underscore the potential benefits of multimodal treatment in this rare malignancy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.